AGIO Stock: Price, Earnings History and SEC Filings
Agios Pharmaceuticals, Inc. (AGIO) last traded at $30.55, down 17.94% on the latest session and down 8.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.69 against an analyst estimate of $-1.86, a beat of 9.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AGIO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.69 | $-1.86 | +9.14% |
| Mar 2026 | Apr 29, 2026 | $-1.69 | $-1.81 | +6.63% |
| Dec 2025 | Feb 12, 2026 | $-1.85 | $-1.97 | +6.09% |
| Sep 2025 | Oct 30, 2025 | $-1.78 | $-1.93 | +7.77% |
AGIO beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How AGIO reacts to earnings
Across its last 8 earnings releases, AGIO moved 4.3% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | Before open | -6.46% |
| 2026-04-29 | Before open | +13.10% |
| 2026-02-12 | Before open | +1.30% |
| 2025-10-30 | Before open | +2.91% |
| 2025-07-31 | Before open | -0.85% |
| 2025-05-01 | Before open | +4.21% |
| 2025-02-13 | Before open | +1.49% |
| 2024-10-31 | Before open | -4.04% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AGIO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $54M | -$413M | -$377M | -764.0% | $-7.12 |
| 2024 | $36M | $674M | -$392M | 1845.9% | $11.64 |
| 2023 | $27M | -$352M | -$297M | -1312.6% | $-6.33 |
| 2022 | $14M | -$232M | -$314M | -1627.8% | $-4.23 |
| 2021 | $0 | $1.6B | -$413M | – | $26.55 |
| 2020 | $0 | -$327M | -$305M | – | $-4.74 |
| 2019 | $118M | -$411M | -$383M | -349.0% | $-6.86 |
| 2018 | $94M | -$346M | -$311M | -366.6% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AGIO
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 18, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · Apr 29, 2026
- 8-K · Apr 29, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
- 10-K · Feb 12, 2026
- 8-K · Feb 12, 2026Results of operations, Financial statements and exhibits
- 8-K · Jan 12, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Oct 30, 2025
Insider filing activity
AGIO insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AGIO news
- Agios Sinks 18% as FDA Delays Sickle Cell Drug Decision to 2027 Despite Being “Launch-Ready”Oct 30, 2026 · tikr.com
- Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)Oct 30, 2026 · seekingalpha.com
- Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAOct 30, 2026 · finance.yahoo.com
- Agios falls on review extension for Pyrukynd label expansionOct 30, 2026 · seekingalpha.com
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- DHR Q3 Earnings Beat on Biotechnology Strength, Sales in LineOct 21, 2026 · finance.yahoo.com
- Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?Oct 20, 2026 · finance.yahoo.com
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.